Shield Therapeutics (STX); Swissmedic approves major extension of Feraccru in Switzerland

Published on 24-04-2019 08:16:12
Author Sparks Team

Shield Therapeutics announced that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted a major extension of the approved indication for Feraccru to now include treatment of all adults with iron deficiency (ID) with or without anaemia.

Carl Sterritt, Shield Therapeutics’ CEO, said, “Together with the new label, we expect the recent positive result from the AEGIS-H2H phase 3b active comparator study of Feraccru versus intravenously delivered Ferinject will have added importance and will provide an enhanced commercial opportunity to Ewo, our Swiss commercial partner. We look forward to working with them to deliver commercial success for Feraccru in Switzerland at the earliest opportunity.”

Share this with friends and colleagues

Company list